ライフサイエンスコーパス: Clostridium difficile

1 and TcdB are the major virulence factors of Clostridium difficile.

2 nzyme, SrtB, is conserved between strains of Clostridium difficile.

3 of TcdB varies between different strains of Clostridium difficile.

4 tion resistance against pathogens, including Clostridium difficile.

5 creasing susceptibility to pathogens such as Clostridium difficile.

6 a to prevent invasion by pathogens including Clostridium difficile.

7 c Escherichia coli, Salmonella enterica, and Clostridium difficile.

8 irculation after infection with the pathogen Clostridium difficile.

9 healthy adults are colonized with toxigenic Clostridium difficile.

10 ation resistance against pathogens including Clostridium difficile.

11 ial infection with Citrobacter rodentium and Clostridium difficile.

12 a, Eggerthella, and the potential pathobiont Clostridium difficile.

13 fluence susceptibility to pathogens, such as Clostridium difficile.

14 re-forming pathogens, Bacillus anthracis and Clostridium difficile.

15 ation among LFAs for influenza, malaria, and Clostridium difficile.

16 Quality control ranges for Clostridium difficile (0.12 to 1 mug/ml) and Eggerthella

17 Clostridium difficile 027/NAP1/BI is the most common C.

18 Clostridium difficile (12.6 to 13.9% prevalence) and nor

19 ens, Staphylococcus aureus Mu50 (SaCwlT) and Clostridium difficile 630 (CdCwlT).

20 nfective aetiology (112/1207 (9.2%)) such as Clostridium difficile (97/1048 (9.3%) tested) or virolog

21 Among these, Clostridium difficile, a major cause of antibiotic-induc

22 Little is known about cell division in Clostridium difficile, a strict anaerobe that causes ser

23 Surveillance testing for Clostridium difficile among pediatric oncology patients

24 lysis of selected nylon-3 copolymers against Clostridium difficile, an important nosocomial pathogen

25 than 30 residents included those related to Clostridium difficile, anaerobes, Candida spp., Streptoc

26 mice datasets, investigating infection with Clostridium difficile and an immune-modulatory probiotic

27 c use and minimizing adverse events, such as Clostridium difficile and antibiotic resistance, have pr

28 TcdB) are produced by the bacterial pathogen Clostridium difficile and are responsible for the pathol

29 (endospores), such as those of the pathogens Clostridium difficile and Bacillus anthracis, are unique

30 outcomes of hospitalized patients tested for Clostridium difficile and determine the correlation betw

31 His work led the discovery of Clostridium difficile and he identified it as the leadin

32 Herein, we establish Clostridium difficile and its enterotoxin A (TcdA) as Py

33 nzymatic activity of DisA-like proteins from Clostridium difficile and Methanocaldococcus jannaschii.

34 applies to the CD27L endolysin that targets Clostridium difficile and the CS74L endolysin that targe

35 The interplay between Clostridium difficile and the host's metabolome is belie

36 ssociation of proton pump inhibitor use with Clostridium difficile and ventilator-associated pneumoni

37 g activity in vivo against Shiga, botulinum, Clostridium difficile, anthrax, and ricin toxins.

38 a key prevention strategy for resistance and Clostridium difficile Antibiotic stewardship programs (A

39 d mortality rates associated with nosocomial Clostridium difficile-associated diarrhea (CDAD), a seri

40 Clostridium difficile-associated diarrhea is a well-reco

41 bacterial drug approved for the treatment of Clostridium difficile-associated diarrhea.

42 Clostridium difficile-associated disease (CDAD) constitu

43 ting toxin B from highly virulent strains of Clostridium difficile (BI/NAP-1/027) in stool.

44 Clostridium difficile (C. difficile) infection (CDI) rat

45 In the intestinal pathogen Clostridium difficile, c-di-GMP inhibits flagellar motil

46 spores of a number of bacterial species and Clostridium difficile carries three bclA genes.

47 Clostridium difficile causes antibiotic-associated diarr

48 In the Clostridium difficile cell wall protein family, we show

49 HAIs were pneumonia (48%), sepsis (20%), and Clostridium difficile colitis (18%).

50 transplantation (FMT) utilized for relapsing Clostridium difficile colitis successfully eradicated co

51 of leptin in the mucosal immune response to Clostridium difficile colitis, a leading cause of nosoco

52 ated hospital length of stay, development of Clostridium difficile colitis, and total hospital cost.

53 ctobacilli in the course of her treatment of Clostridium difficile colitis.

54 ical history significant for acid reflux and Clostridium difficile colitis.

55 re occurrence of surgical site infection and Clostridium difficile colitis.

56 No Clostridium difficile colonization or C. difficile infec

57 The diarrheal pathogen Clostridium difficile consists of at least six distinct

58 r expressing the HIV-1-derived Gag Ag or the Clostridium difficile-derived toxin B resulted in signif

59 nucleic acid amplification tests (NAAT) for Clostridium difficile diagnosis and their impact on stoo

60 There is no stand-alone Clostridium difficile diagnostic that can sensitively an

61 Many factors may cause diarrhoea, including Clostridium difficile, drugs (e.g. laxatives, antibiotic

62 s that are not reported at this institution (Clostridium difficile, enteroaggregative Escherichia col

63 an acquire multidrug-resistant organisms and Clostridium difficile from inadequately disinfected envi

64 eliable tools for the detection of toxigenic Clostridium difficile from unformed (liquid or soft) sto

65 Successful sequencing of the Clostridium difficile genome requires high-quality genom

66 scherichia coli, Salmonella typhimurium, and Clostridium difficile genomes.

67 In the past decade Clostridium difficile has become a bacterial pathogen of

68 Clostridium difficile has become one of the most common

69 In the past decade, Clostridium difficile has emerged as an important gut pa

70 Unlike in B. subtilis, SpoIIQ of Clostridium difficile has intact LytM zinc-binding motif

71 and metagenomic shotgun sequencing (MSS) for Clostridium difficile identification in diarrhea stool s

72 , drug-product-related impurities of an anti-Clostridium difficile IgG1 mAb drug substance were profi

73 Diego, CA) tests for detection of toxigenic Clostridium difficile in 459 stool samples (9.4% positiv

74 The role of Clostridium difficile in causing disease in infants is u

75 The horizontal transmission of Clostridium difficile in the hospital environment is dif

76 for treatment of recurrent infections (i.e., Clostridium difficile) in the human gut and as a general

77 Drivers of differences in Clostridium difficile incidence across acute and long-te

78 were rated >6 in all criteria: 2 measures of Clostridium difficile incidence, incidence of drug-resis

79 h daptomycin (MIC90 0.5 vs 2 mug/mL) against Clostridium difficile including NAP1 epidemic strains.

80 8%) of 25 asymptomatic carriers of toxigenic Clostridium difficile, including 93% with skin and/or en

81 zole: 2), and one patient was diagnosed with Clostridium difficile infection (0 vs 1).

82 ently encountered infectious etiologies were Clostridium difficile infection (13.3% and 11.8%, respec

83 The incidence of Clostridium difficile infection (CDI) and associated mor

84 plification tests (NAATs) do not distinguish Clostridium difficile infection (CDI) and asymptomatic C

85 e advances in the diagnosis and treatment of Clostridium difficile infection (CDI) and prevention eff

86 es suggest that most cases of hospital-onset Clostridium difficile infection (CDI) are unrelated to o

87 methods may underestimate the true burden of Clostridium difficile infection (CDI) because they fail

88 Prevention and management of Clostridium difficile infection (CDI) can be improved by

89 Clostridium difficile infection (CDI) can cause severe d

90 Little is known about pediatric Clostridium difficile infection (CDI) epidemiology.

91 Clostridium difficile infection (CDI) following antibiot

92 Recurrent or refractory Clostridium difficile infection (CDI) has become an incr

93 dences of antibiotic-associated diarrhea and Clostridium difficile infection (CDI) has been demonstra

94 icrobiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited t

95 igh sensitivity of PCR assays for diagnosing Clostridium difficile infection (CDI) has greatly reduce

96 osing to, or modulating disease severity in, Clostridium difficile infection (CDI) has not been inves

97 The incidence of Clostridium difficile infection (CDI) has risen dramatic

98 Patients with recurrent Clostridium difficile infection (CDI) have a >/=60% risk

99 Since 2000, the incidence and severity of Clostridium difficile infection (CDI) have increased.

100 The currently available diagnostics for Clostridium difficile infection (CDI) have major limitat

101 id suppression medication is associated with Clostridium difficile infection (CDI) in adults and is i

102 dies on risk factors for and transmission of Clostridium difficile infection (CDI) in China have been

103 This article defines the risk factors for Clostridium difficile infection (CDI) in hospitalized ch

104 Clostridium difficile infection (CDI) incidence has incr

105 Clostridium difficile infection (CDI) is a common compli

106 Clostridium difficile infection (CDI) is a frequent comp

107 Clostridium difficile infection (CDI) is a major burden

108 Clostridium difficile infection (CDI) is a major cause o

109 Clostridium difficile infection (CDI) is a serious compl

110 Clostridium difficile infection (CDI) is an important ca

111 Clostridium difficile infection (CDI) is an important ho

112 Clostridium difficile infection (CDI) is associated with

113 Clostridium difficile infection (CDI) is common after li

114 Clostridium difficile infection (CDI) is facilitated by

115 mal therapy for critically ill patients with Clostridium difficile infection (CDI) is not known.

116 f fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) is not well-known.

117 Recurrent Clostridium difficile infection (CDI) is of particular c

118 Clostridium difficile infection (CDI) is the leading hea

119 Clostridium difficile infection (CDI) is the most common

120 Clostridium difficile infection (CDI) is the most common

121 gel electrophoresis type 1 (NAP1) strain in Clostridium difficile infection (CDI) outcome.

122 Managing recurrent Clostridium difficile infection (CDI) presents a signifi

123 Clostridium difficile infection (CDI) ranges from asympt

124 Variation in Clostridium difficile infection (CDI) rates between heal

125 This study analyzes and reports Clostridium difficile infection (CDI) rates, risk factor

126 innate immune response to the resolution of Clostridium difficile infection (CDI) remains incomplete

127 Clostridium difficile infection (CDI) represents an impo

128 Clostridium difficile infection (CDI) represents the mos

129 Recurrent Clostridium difficile infection (CDI) with poor response

130 for the efficacy of probiotics in preventing Clostridium difficile infection (CDI), but guidelines do

131 (FT) is a promising treatment for recurrent Clostridium difficile infection (CDI), but its true effe

132 polymorphism rs4073/-251T >A predisposes to Clostridium difficile infection (CDI), but this associat

133 catheter-associated urinary tract infection, Clostridium difficile infection (CDI), central line-asso

134 Unfortunately, the rise of Clostridium difficile infection (CDI), particularly in e

135 During treatment of Clostridium difficile infection (CDI), patterns of patho

136 Clostridium difficile infection (CDI), the most common h

137 es have evaluated risk factors for recurrent Clostridium difficile infection (CDI), the vast majority

138 ens, including acute kidney injury (AKI) and Clostridium difficile infection (CDI), were also conside

139 peutic effects of dietary supplementation on Clostridium difficile infection (CDI).

140 e to severe disease and treatment failure in Clostridium difficile infection (CDI).

141 is a highly effective therapy for recurrent Clostridium difficile infection (CDI).

142 is a highly effective therapy for recurrent Clostridium difficile infection (CDI).

143 ease states, and the prototypical example is Clostridium difficile infection (CDI).

144 he gastrointestinal microbiome to facilitate Clostridium difficile infection (CDI).

145 considered important for protection against Clostridium difficile infection (CDI).

146 -Counterpoint on the laboratory diagnosis of Clostridium difficile infection (CDI).

147 rope and the United States for patients with Clostridium difficile infection (CDI).

148 h care-onset health care facility-associated Clostridium difficile infection (HO-CDI) is overdiagnose

149 actam (PIP/TAZO) shortage and hospital-onset Clostridium difficile infection (HO-CDI) risk in 88 US m

150 Recurrent Clostridium difficile infection (RCDI) is associated wit

151 utic modality for the treatment of recurrent Clostridium difficile infection (RCDI).

152 ed hospitalization, and hospitalization with Clostridium difficile infection [CDI]) were associated w

153 Clostridium difficile infection after LT was associated

154 ts it has been successfully used in cases of Clostridium difficile infection and IBD, although contro

155 We also assessed rates of Clostridium difficile infection and potential allergic r

156 ctors affecting a person's susceptibility to Clostridium difficile infection are well-understood, lit

157 tic withdrawal regimen may resolve recurrent Clostridium difficile infection as effectively as fecal

158 We identified 12 patients with Clostridium difficile infection between July 2011 and Ma

159 s is not observed in subjects with recurrent Clostridium difficile infection but is observed in the s

160 cottish government issued a target to reduce Clostridium difficile infection by 30% in 2 years.

161 Variations in testing for Clostridium difficile infection can hinder patients' car

162 Clostridium difficile infection causes severe complicati

163 The epidemic of Clostridium difficile infection fueled by new virulent s

164 The incidence of Clostridium difficile infection has increased among chil

165 Clostridium difficile infection has increased in inciden

166 Clostridium difficile infection in LT recipients was ass

167 We compared rates of recurrent Clostridium difficile infection in patients receiving or

168 The detection and diagnosis of Clostridium difficile infection in pediatric populations

169 The magnitude and scope of Clostridium difficile infection in the United States con

170 Clostridium difficile infection is a growing problem in

171 Clostridium difficile infection is a serious and highly

172 eudomembranous enterocolitis associated with Clostridium difficile infection is an important cause of

173 Disease associated with Clostridium difficile infection is caused by the actions

174 Their use as probiotics for prevention of Clostridium difficile infection is prevalent among consu

175 Clostridium difficile infection is the leading cause of

176 Clostridium difficile infection is the leading cause of

177 Clostridium difficile infection is the main cause of hea

178 Clostridium difficile infection is the most common cause

179 Clostridium difficile infection is the most common healt

180 It has been thought that Clostridium difficile infection is transmitted predomina

181 mine whether the reductions in recurrence of Clostridium difficile infection observed with fidaxomici

182 Clostridium difficile infection occurred in 27 (14%) of

183 Clostridium difficile infection often occurred soon afte

184 reports found addressed the use of FMTs for Clostridium difficile infection or inflammatory bowel di

185 Whereas many antibiotics increase risk of Clostridium difficile infection through dysbiosis, epide

186 Rates of nosocomial Clostridium difficile infection were compared by using i

187 cohort of 109 subjects treated for recurrent Clostridium difficile infection with fecal microbiota tr

188 t serious cephalosporin-associated ADRs were Clostridium difficile infection within 90 days (0.91%),

189 ated charges for inflammatory bowel disease, Clostridium difficile infection, and chronic liver disea

190 with outcomes (antibiotic-days, incidence of Clostridium difficile infection, and in-hospital mortali

191 ffective in treating relapsing or refractory Clostridium difficile infection, but practical barriers

192 viously used to cure patients with recurrent Clostridium difficile infection, could also protect agai

193 for the same infection, acute kidney injury, Clostridium difficile infection, or drug-related adverse

194 py, and frequency of complications including Clostridium difficile infection, readmission, and all-ca

195 ation (FMT) is effective in the treatment of Clostridium difficile infection, where efficacy correlat

196 acious and inexpensive therapy for recurrent Clostridium difficile infection, yet its safety is thoug

197 nsecutive, evaluable patients with recurrent Clostridium difficile infection.

198 mycin antibiotic treatment and opportunistic Clostridium difficile infection.

199 contributes to the pathology observed during Clostridium difficile infection.

200 idian Bioscience, Inc.) for the diagnosis of Clostridium difficile infection.

201 bleed, ventilator-associated pneumonia, and Clostridium difficile infection.

202 and fidaxomicin are therapies of choice for Clostridium difficile infection.

203 ns about promoting antibiotic resistance and Clostridium difficile infection.

204 or-associated complication or pneumonia, and Clostridium difficile infection; minor outcomes included

205 Clostridium difficile infections (CDI) are a growing con

206 n to form the vegetative cells that initiate Clostridium difficile infections (CDI).

207 BACKGROUND & AIMS: Studies of Clostridium difficile infections (CDIs) among individual

208 ast 50 years for the treatment of refractory Clostridium difficile infections (RCDIs) in adults, it h

209 al microbiota transplantation to face severe Clostridium difficile infections and to perform decoloni

210 The symptoms of Clostridium difficile infections are caused by two exoto

211 biotic-based strategies for the treatment of Clostridium difficile infections disrupt indigenous micr

212 The prevalence of Clostridium difficile infections has increased due to th

213 The control of Clostridium difficile infections is an international cli

214 han 9000 nosocomial infections, 1000 to 5000 Clostridium difficile infections, and 2 to 6 cases of an

215 den of antimicrobial-resistant organisms and Clostridium difficile infections, halting unnecessary an

216 , ventilator-associated pneumonia (VAP), and Clostridium difficile infections.

217 Clostridium difficile is a cause of antibiotic-associate

218 Clostridium difficile is a clinically important pathogen

219 Clostridium difficile is a clinically significant pathog

220 Clostridium difficile is a gastrointestinal pathogen but

221 Clostridium difficile is a Gram-positive bacterium commo

222 Clostridium difficile is a Gram-positive, spore-forming

223 Clostridium difficile is a leading cause of antibiotic-a

224 The spore-forming bacterial pathogen Clostridium difficile is a leading cause of health-care-

225 ciated infection with the bacterial pathogen Clostridium difficile is a major cause of morbidity and

226 Clostridium difficile is a major nosocomial pathogen tha

227 Clostridium difficile is a major, life-threatening hospi

228 Clostridium difficile is a prominent nosocomial pathogen

229 jor cause of antibiotic-associated diarrhea, Clostridium difficile is a serious problem in health car

230 Clostridium difficile is a significant concern as a noso

231 Clostridium difficile is an anaerobic Gram-positive bact

232 Clostridium difficile is an anaerobic pathogen that form

233 Clostridium difficile is an important nosocomial pathoge

234 Clostridium difficile is an important pathogen causing s

235 tion with the opportunistic enteric pathogen Clostridium difficile is an increasingly common clinical

236 Clostridium difficile is currently the leading cause of

237 ecal toxin negative (FT-) in transmission of Clostridium difficile is currently unknown.

238 The pathogenicity of Clostridium difficile is linked to its ability to produc

239 Clostridium difficile is one of the most common nosocomi

240 Clostridium difficile is the cause of antibiotics-associ

241 The spore-forming gut bacterium Clostridium difficile is the leading cause of antibiotic

242 Clostridium difficile is the leading cause of hospital-a

243 Clostridium difficile is the leading cause of infectious

244 Clostridium difficile is the most common cause of health

245 Clostridium difficile is the most common hospital acquir

246 Clostridium difficile is the most commonly identified pa

247 Clostridium difficile is the most commonly reported noso

248 Clostridium difficile is the most frequently identified

249 Clostridium difficile is the most important enteropathog

250 Clostridium difficile is the principal cause of nosocomi

251 Clostridium difficile is widely publicised as a problem

252 Clostridium difficile isolates were typed and compared w

253 ntamination, colonization, or infection with Clostridium difficile, methicillin-resistant Staphylococ

254 iotic exposures, and the prevalence rates of Clostridium difficile, methicillin-resistant Staphylococ

255 ts to the health service and predisposing to Clostridium difficile, methicillin-resistant Staphylococ

256 The anaerobic gastrointestinal pathogen Clostridium difficile must form a metabolically dormant

257 rienced a major outbreak associated with the Clostridium difficile NAP1/027/BI strain.

258 Diarrhoea positive for Clostridium difficile occurred in two patients (<1%) in

259 ed in colonic neurons of human patients with Clostridium difficile or ulcerative colitis.

260 No effect was observed on incidence of Clostridium difficile (OR 1.02, 95% CI 0.34-3.01), and m

261 on of spores is critical for the survival of Clostridium difficile outside the host gastrointestinal

262 Clostridium difficile PCR ribotype 265 (toxin A negative

263 orders for ovum and parasite (O&P) exams and Clostridium difficile PCR.

264 Clostridium difficile (Peptoclostridium difficile) is a

265 ACKGROUND & AIMS: Nosocomial infections with Clostridium difficile present a considerable problem des

266 w that toxins A or B of the enteric pathogen Clostridium difficile recapitulate the salient features

267 Clostridium difficile remains the leading cause of nosoc

268 Clostridium difficile rivals methicillin-resistant Staph

269 Clostridium difficile RT244 was associated with more sev

270 pansion of several potential pathogens (e.g. Clostridium difficile, Salmonella, and Escherichia coli)

271 ansplantation led to resolution of recurrent Clostridium difficile, significantly decreased recurrent

272 obiota, which consequently enables toxigenic Clostridium difficile species to proliferate and cause i

273 ective and easy-to-use methods for detecting Clostridium difficile spore contamination would be usefu

274 hotspots associated with mobile elements in Clostridium difficile ST6 and a previously undescribed 3

275 infections (HAIs), including those caused by Clostridium difficile, Staphylococcus aureus, Pseudomona

276 Clostridium difficile strain BI/NAP1/027 is associated w

277 Clostridium difficile strains within the hypervirulent c

278 Hypervirulent Clostridium difficile strains, which are associated with

279 xin (CTB5) and a subfragment of toxin A from Clostridium difficile (TcdA-A2).

280 Clostridium difficile TcdB (2366 amino acid residues) is

281 TcdB is one of the key virulence factors of Clostridium difficile that is responsible for causing se

282 n that we identified from the human pathogen Clostridium difficile The crystal structure shows that t

283 inococcus obeum, Salmonella typhimurium, and Clostridium difficile) to quantify, expand, and characte

284 ability of Gram-positive species, including Clostridium difficile, to produce Type IV pili.

285 The contribution of Clostridium difficile toxin A and B (TcdA and TcdB) to c

286 Clostridium difficile toxin B (TcdB) is a critical virul

287 or Pyrin inflammasomes by nigericin (NG) or Clostridium difficile toxin B (TcdB), respectively.

288 We have shown previously that Clostridium difficile toxin B (ToxB), an inhibitor of Rh

289 Clostridium difficile toxin was subsequently detected in

290 ly from stool specimens: Campylobacter spp., Clostridium difficile (toxin A/B), Plesiomonas shigelloi

291 Prototypes are Clostridium difficile toxins A and B, which cause antibi

292 acid amplification test for the detection of Clostridium difficile toxins in stool specimens, with th

293 ve and quantitative methods for detection of Clostridium difficile toxins provide new tools for diagn

294 ty, produce the actin-ADP ribosylating toxin Clostridium difficile transferase (CDT).

295 CDT (Clostridium difficile transferase) is a binary, actin AD

296 y additionally produce the binary CDT toxin (Clostridium difficile transferase) that ADP-ribosylates

297 Accurate tracking of Clostridium difficile transmission within healthcare set

298 Simplexa Clostridium difficile universal direct PCR, a real-time

299 Clostridium difficile was the most commonly reported pat

300 his setting, such as Cryptosporidiumspp. and Clostridium difficile, were detected with the GPP.